NCT06372626View on ClinicalTrials.gov

Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

May 30, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

August 31, 2026

Conditions
Neuroendocrine Carcinoma
Interventions
BIOLOGICAL

ZG005

"ZG005 for dose escalations are set as 10mg/kg, 20mg/kg, and the other doses after discussion. intravenous infusion, once every 3 weeks.~ZG005 for dose expansion will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage."

DRUG

Etoposide

IV infusion

DRUG

Cisplatin

IV infusion

DRUG

Placebo

0.9% Sodium Chloride Injection

Trial Locations (1)

100853

RECRUITING

Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY